These data provided the rationale for the phase III EMERALD study comparing the efficacy and safety of elacestrant versus standard-of-care endocrine treatment (fulvestrant or AI) in patients with ER+, HER2− advanced breast cancer (66). Here, ESR1 is linked to breast carcinoma.